Clinical Trials Logo

Bioavailability clinical trials

View clinical trials related to Bioavailability.

Filter by:

NCT ID: NCT06306911 Recruiting - Bioavailability Clinical Trials

Bioavailability of Aronia Melanocarpa

Start date: March 2024
Phase: N/A
Study type: Interventional

The main objective of this study is to study the bioavailability and kinetics of acute Aronia Melanocarpa supplementation in healthy young (18-35 years) and older adults (55-75 years) adults. During the test day, participants will ingest a drink consisting of Aronia Melanocarpa extract (AME). The bioavailability and kinetics of AME will be assessed via frequent blood sampling, urine collection, and faecal sampling, in which AME and metabolite profiles will be quantified.

NCT ID: NCT06214338 Not yet recruiting - Bioavailability Clinical Trials

Blood Bioavailability of Two Different Doses of a β-alanine Supplement (BIo-β)

Bio-ß
Start date: February 12, 2024
Phase: N/A
Study type: Interventional

The purpose of this study is to To study the blood bioavailability of a sustained-release β-alanine granulated supplement of two different doses (10 g and 20 g).

NCT ID: NCT06177483 Enrolling by invitation - Bioavailability Clinical Trials

Bioavailability Evaluation of curQ+ Curcumin Formulation

Start date: February 25, 2024
Phase: N/A
Study type: Interventional

This study is intended to evaluate how significantly a proprietary curcumin formulation (curQ+®) results in greater bioavailability compared to 95% curcumin extract over a 6-hour time period following a single oral dose in healthy men & women.

NCT ID: NCT06098001 Active, not recruiting - Bioavailability Clinical Trials

Bioavailability Study of Hemp Phenolics

Start date: September 15, 2023
Phase: N/A
Study type: Interventional

The aim is to determine the bioavailability of the polyphenol fraction form a commercially available hemp hull fiber at two different amounts in generally healthy adults. Additional objectives include determining specific metabolites produced over a 24 to 48-hour period following the hemp fiber consumption. Subjects will consume a study pudding that will be used to deliver a low and a high dose fiber product. Blood samples will be collected to measure background levels of metabolites. At day 0 participants will consume a low dose study product and day 6 the high dose study product and provide blood samples over an 8 hr period after study product consumption, to be followed by a 24 hr blood sample and 48 hr blood sample. Additionally following the low / high dose study product 24 and 48 h urine samples will be collected.

NCT ID: NCT06043739 Completed - Bioavailability Clinical Trials

Relative Bioavailability and Effect of Food Study With an Oral Mini-tablet Formulation of Filgotinib in Healthy Subjects

Start date: September 22, 2023
Phase: Phase 1
Study type: Interventional

Open label study to assess relative bioavailability of filgotinib oral mini-tablet versus oral tablet formulation and effect of food on the mini-tablet formulation.

NCT ID: NCT05967377 Completed - Pharmacokinetics Clinical Trials

Evaluating the Pharmacokinetic Parameters and Relative Bioavailability of Sorafenib (XS005) in Healthy Male Subjects

Start date: November 16, 2018
Phase: Phase 1
Study type: Interventional

This is a single centre, open-label, randomised, single dose, 3-way crossover comparative (PK) and bioavailability study in healthy male subjects comparing a 200 mg Sorafenib (Nexavar®) reference tablet (Regimen A) to XS005 Sorafenib Capsule A, 2 x 50 mg (Regimen B) and XS005 Sorafenib Tablet A,100 mg (Regimen C) formulation. It is planned to enroll 15 subjects who will receive single oral doses of investigational medicinal product (IMP) across 3 treatment periods.

NCT ID: NCT05840848 Completed - Bioavailability Clinical Trials

Effect of Iron and Zinc Supplementation on B-carotene Bioavailability in Healthy Males

Start date: November 21, 2017
Phase: N/A
Study type: Interventional

In vitro studies found supplemental levels of iron and zinc to inhibit the micellization and cellular uptake of β-carotene. Here, we investigated this in vivo, in a double-blind 3-arm crossover human trial. Healthy males (n=6) ingested, with breakfast, a single dose of 15 mg β-carotene in combination with either a placebo, 25 mg iron or 30 mg zinc capsule. Blood samples were collected at baseline and hourly for 10 hours. The triacylglycerol-rich fraction (TRF) was analysed for concentrations of β-carotene and plasma for β-carotene, retinol, triacylglycerols, LDL- and HDL-cholesterol.

NCT ID: NCT05835258 Completed - Bioavailability Clinical Trials

Oral Bioavailability of Two Melatonin Supplements

MELFENIL
Start date: May 30, 2023
Phase: N/A
Study type: Interventional

Results from several clinical studies show that orally administered melatonin has low bioavailability and a very short half-life. Phenyl capsaicin, a synthetic analogue of capsaicin, might increase its bioavailability by inhibiting the enzymes involved in its hepatic metabolism. Thus, the hypothesis of the present study is that the administration of melatonin supplement with phenyl capsaicin presents greater bioavailability than a melatonin supplement that does not contain phenyl capsaicin.

NCT ID: NCT05826899 Enrolling by invitation - Bioavailability Clinical Trials

A Stable Isotope Study to Evaluate the Bioavailability of an Oat Protein-based Iron Delivery System

Start date: April 3, 2023
Phase: N/A
Study type: Interventional

In the current study, the OAT fibril - Fe SA (Fe-oat 1) and OAT fibril - Fe NaOH (Fe-oat 2) will both be studied in vivo, alone are oat fibril powder add iron supplement is soluble in water and oat fibril powder add iron supplement is soluble in water in a food matrix (acai puree and honey) to assess their promise as Fe food fortificants. This first in human study to bioavailability assessment and adverse effect of the OAT fibril - Fe SA (Fe-oat 1), OAT fibril - Fe NaOH (Fe-oat 2) and in a food matrix to assess their promise as Fe food fortificants. This study will be conducted with the following objectives. 1. To conduct a stable Fe isotope study to evaluate the bioavailability of OAT-Fe formulated using two reducing agents (Fe-oat 1 and Fe-oat-2) and compared to FeSO4. 2. To compare the performance of Fe-oat 1 and 2 in a food matrix containing Fe inhibitors, (acai puree and honey) in comparison to FeSO4 in a similar meal matrix.

NCT ID: NCT05774704 Recruiting - Safety Clinical Trials

Curcumin and Retinal Study

Start date: August 21, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

To test how two weeks of curcumin supplementation would cross the blood brain barrier (BBB) and attach to amyloid beta proteins, to assess the feasibility (safety and bioavailability), and to explore the resulting abundance/composition of gut microbiota.